Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

61.80 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
BridgeBio to Participate in November Investor Conferences
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Earnings Scheduled For October 29, 2025
 
Via Benzinga
Earnings Outlook For BridgeBio Pharma
 
Via Benzinga
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
The company easily beat third-quarter expectations and issued guidance that widely topped forecasts. 
Via Investor's Business Daily
BridgeBio Pharma (NASDAQ:BBIO) Q3 2025 Revenue Beat Overshadowed by Widened Loss
BridgeBio Pharma's Q3 2025 earnings show a major revenue beat driven by Attruby sales, but a widened quarterly loss led to a negative market reaction. 
Via Chartmill
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder
BridgeBio's Encaleret met its Phase 3 endpoint in ADH1, with 76% achieving calcium targets, supporting plans for FDA and EMA submissions in 2026. 
Via Benzinga
BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results
76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment. 
Via Stocktwits
BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High
A second positive "domino" fell for BridgeBio on Wednesday after the company reported promising results in a genetic disease. 
Via Investor's Business Daily
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
From BridgeBio Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial
BridgeBio now intends to file a new drug application for the therapy's approval in the first half of 2026. 
Via Stocktwits
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition
BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study. 
Via Benzinga
BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival
The company ran an exploratory analysis of its drug, Attruby, in patients with cardiomyopathy due to TTR amyloidosis. 
Via Investor's Business Daily
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Inc (NASDAQ:BBIO) Shows Strong Technical Setup for Potential Breakout
BridgeBio Pharma (BBIO) shows strong technicals with a perfect 10 rating. Currently in a consolidation pattern, it may be poised for a breakout above resistance, offering a potential entry for... 
Via Chartmill
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension
From BridgeBio Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.